US Stock MarketDetailed Quotes
GMAB Genmab
- 20.650
- -0.140-0.67%
Close Nov 26 16:00 ET
- 20.650
- 0.0000.00%
Post 17:43 ET
13.12BMarket Cap20.30P/E (TTM)
20.760High20.460Low1.16MVolume20.760Open20.790Pre Close23.86MTurnover0.18%Turnover Ratio22.25P/E (Static)635.14MShares32.88052wk High2.92P/B12.98BFloat Cap20.34052wk Low--Dividend TTM628.37MShs Float49.070Historical High--Div YieldTTM1.44%Amplitude16.240Historical Low20.609Avg Price1Lot Size
About Genmab Company
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Company Profile
SymbolGMAB
Company NameGenmab
Listing DateJul 18, 2019
Issue Price17.75
Founded1998
CEODr. Jan G. J. van de Winkel, PhD
MarketNASDAQ
Employees2204
Securities TypeDR
ADS Ratio10.0 : 1.0
Fiscal Year Ends12-31
AddressCarl Jacobsens Vej 30,Valby
CityCopenhagen
ProvinceCentral Denmark
CountryDenmark
Zip Code2500
Phone45-70-20-27-28
Websitehttp://www.genmab.com
Company Executives
- Name
- Position
- Salary
- Dr. Jan G. J. van de Winkel, PhD
- President and Chief Executive Officer
- 44.30M
- Birgitte Stephensen
- Executive Vice President and Chief Legal Officer
- 10.10M
- Christopher Cozic
- Executive Vice President and Chief People Officer
- 13.20M
- Dr. Tahamtan Ahmadi, PhD
- Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
- 19.80M
- Anthony Pagano
- Executive Vice President and Chief Financial Officer
- 19.60M
- Anthony Mancini
- Executive Vice President and Chief Operating Officer
- 21.80M
- Dr. Martine J. van Vugt, PhD
- Executive Vice President and Chief Strategy Officer
- 8.90M
- Dr. Judith Klimovsky, M.D.
- Executive Vice President and Chief Development Officer
- 21.70M
- Dr. Mijke Zachariasse
- Director, Vice President and Head of Antibody Research Materials
- 1.10M
- Pernille Erenbjerg
- Deputy Chairman of the Board
- 2.10M
- Deirdre P. Connelly
- Chairman of the Board
- 2.80M
- Takahiro Hamatani
- Director and Senior Director, Finance Japan
- 800.00K
- Anders Gersel Pedersen, M.D.,PhD
- Director
- 1.70M
- Martin Schultz
- Director, Senior Director and Head of Development Business Partnership and Strategy
- 800.00K
- Elizabeth G. O’Farrell
- Independent Director
- 1.90M
- Dr. Paolo Paoletti, M.D.
- Independent Director
- 1.50M
- Rolf Karl-Heinz Hoffmann
- Independent Director
- 1.50M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data